Sevabertinib Makes HER2 Testing Actionable in NSCLC

The FDA’s September 9, 2026, decision creates a biomarker-defined treatment option for adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer whose tumors harbor an activating HER2 kinase-domain mutation. The indication applies after prior systemic therapy and depends on mutation detection using an FDA-authorized test.

That wording matters. The approval is not for all tumors described as HER2-positive, and it does not make immunohistochemistry, gene amplification or HER2 expression interchangeable with a qualifying kinase-domain mutation. It also does not establish sevabertinib as initial therapy or as a treatment for earlier-stage disease.

Who falls within the new indication

The eligible population is narrow and defined by disease setting, histology, molecular finding and treatment history. Patients must be adults with locally advanced or metastatic nonsquamous NSCLC that has progressed after prior systemic treatment. Their tumors must contain an activating mutation in the HER2 kinase domain, detected by a test authorized by the FDA for this purpose.

HER2 is encoded by ERBB2. Although HER2 expression, amplification and mutation can all be reported in lung cancer, they are biologically and clinically distinct findings. The sevabertinib indication is tied to activating kinase-domain mutations rather than to HER2 status in the broad sense used in some other cancers. A pathology report stating only “HER2-positive” may therefore be insufficient to determine eligibility.

The nonsquamous restriction is equally important. The approval should not be generalized to squamous NSCLC, small-cell lung cancer or other HER2-altered solid tumors. Nor does detection of an ERBB2 alteration automatically establish that it is an activating kinase-domain mutation covered by the companion or complementary diagnostic indication.

For laboratories and care teams, the practical question is not simply whether ERBB2 was included on a sequencing panel. The report must identify the specific variant, establish that the assay is FDA-authorized for the indicated use and provide enough information to determine whether the alteration meets the drug label’s definition. When older testing is incomplete, used a nonauthorized assay or reported an ambiguous alteration, review with molecular pathology may be needed before treatment eligibility is inferred.

What supports the regulatory decision

The FDA granted accelerated rather than traditional approval. This pathway permits earlier authorization for serious diseases when a drug shows an effect on a surrogate or intermediate clinical endpoint considered reasonably likely to predict clinical benefit. For oncology drugs, that evidence commonly comes from tumor response and the durability of those responses rather than from demonstrated improvement in overall survival.

The regulatory evidence for sevabertinib came from a nonrandomized clinical development program in patients with advanced HER2-mutated NSCLC. The FDA based the decision on objective response and duration of response in the molecularly selected population. There was no randomized comparator, so the evidence cannot establish that sevabertinib improves survival or quality of life relative to chemotherapy, immunotherapy, another HER2-directed therapy or supportive care.

A single-arm response result can show antitumor activity, particularly when responses are independently assessed and sustained. It cannot fully separate the treatment effect from patient selection, assessment schedules, subsequent treatment or the natural history of a molecular subgroup. Cross-trial comparisons are especially unreliable because eligibility criteria, prior therapies, mutation distributions, central nervous system disease and response-assessment methods may differ.

The FDA decision notice and prescribing information are the appropriate sources for the exact response estimate, confidence interval, duration-of-response findings, analysis population and safety data supporting the indication. Those numerical results should not be extrapolated to patients outside the labeled population or to HER2 alterations that were not represented in the regulatory analysis.

What changes for testing and care pathways

The immediate consequence is that comprehensive molecular profiling has another directly actionable output in advanced nonsquamous NSCLC. Testing pathways should be capable of identifying ERBB2 kinase-domain mutations with sufficient specificity to distinguish them from amplification, overexpression and variants without established activating significance.

The requirement for an FDA-authorized test also has operational consequences. Institutions may need to confirm whether their current tissue or plasma assay is covered, whether the relevant specimen type is authorized and whether a result from an outside laboratory can be used for labeled treatment selection. The FDA maintains a list of cleared or approved companion diagnostic devices, but the drug label and diagnostic labeling remain controlling because authorizations can be assay- and specimen-specific.

A negative result requires context. Tumor-only testing can fail because of inadequate tissue, low tumor content or limited panel coverage. Plasma testing can also produce a false-negative result when little tumor DNA is shed into circulation. The approval does not by itself dictate a universal testing sequence, but it strengthens the rationale for obtaining an informative molecular result before concluding that a patient lacks an actionable HER2 mutation.

The decision may also affect policy and coverage. Payers and health systems will have to align access to sevabertinib with access to the required diagnostic, including specimen acquisition, sequencing and expert interpretation. A drug approval that depends on a molecular result has limited practical value if testing is delayed, unavailable or reported in a way that obscures whether the alteration qualifies.

Why accelerated approval requires continued scrutiny

Accelerated approval is conditional in evidentiary terms. Continued authorization can depend on completion of confirmatory studies that verify clinical benefit. The FDA may modify or withdraw an indication if required trials fail to confirm benefit, are not completed with due diligence or show that the drug is not safe or effective under its labeled conditions.

Important unanswered questions include comparative efficacy, overall survival, patient-reported outcomes and the optimal treatment sequence after other HER2-directed therapy. Evidence may also be limited for uncommon mutation subtypes, patients with active or untreated brain metastases, people with poor performance status and groups underrepresented in the supporting study.

Safety interpretation should remain anchored to the prescribing information. Class expectations are not a substitute for drug-specific data, and adverse-event risks seen with other HER2 inhibitors should not be assumed to occur at the same frequency or severity with sevabertinib. Clinicians also need mature evidence on treatment discontinuation, dose modification and longer-term toxicities.

The central limitation is the nonrandomized evidence base. Tumor response can support accelerated approval, but it is not proof of longer survival, better function or superiority to existing care. The confirmatory program will determine whether the observed activity translates into clinical benefit and how sevabertinib should be positioned among therapies for HER2-mutated NSCLC.

Questions clinicians ask

Does any HER2-positive result establish eligibility?

No. The indication concerns an activating HER2 kinase-domain mutation, not HER2 expression or amplification alone. The report should identify the specific ERBB2 variant, and eligibility should be checked against the drug label and the FDA-authorized diagnostic’s intended use.

Can a laboratory-developed sequencing result be used?

The approval requires an FDA-authorized test, so assay status cannot be assumed from panel size or laboratory accreditation. Clinicians should verify the assay, specimen type and authorized intended use; an outside or laboratory-developed result may require confirmation if it does not meet the label’s diagnostic requirement.

Does accelerated approval mean survival benefit is established?

No. The decision is based on antitumor response and its durability rather than randomized evidence of improved overall survival. Continued approval may depend on confirmatory evidence, and the FDA can reassess the indication if clinical benefit is not verified.

Should testing wait until disease progression?

The approval does not prescribe a universal testing schedule. However, because eligibility depends on a specific molecular result and testing can be delayed by inadequate tissue or uninformative plasma, obtaining comprehensive profiling early in the advanced-disease pathway can preserve treatment options after prior systemic therapy.

References

1. FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer — US Food and Drug Administration, 2026
2. Accelerated Approval Program — US Food and Drug Administration, 2026
3. List of Cleared or Approved Companion Diagnostic Devices — US Food and Drug Administration, 2026